Literature DB >> 18437302

Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.

L Mark Fisher1, Xiao-Su Pan.   

Abstract

DNA gyrase and DNA topoisomerase (topo) IV are the bacterial targets of coumarin and quinolone antimicrobial agents. Widespread resistance to clinically important antibiotics such as beta-lactams and macrolides has stimulated the development of novel gyrase and topo IV inhibitors especially against Streptococcus pneumoniae and other Gram-positive pathogens. Here, we describe how gyrase and topo IV activities are measured and how inhibitors of these enzymes may be assayed, focusing as a paradigm on DNA supercoiling by S. pneumoniae gyrase, DNA decatenation by S. pneumoniae topo IV, and DNA cleavage by both enzymes. These approaches provide mechanistic insight on inhibitor action and allow identification of dual gyrase/topo IV targeting agents that can minimize the emergence of bacterial resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437302     DOI: 10.1007/978-1-59745-246-5_2

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  9 in total

1.  Nybomycin inhibits both types of E. coli DNA gyrase - fluoroquinolone-sensitive and fluoroquinolone-resistant.

Authors:  Dmitrii I Shiriaev; Alina A Sofronova; Ekaterina A Berdnikovich; Dmitrii A Lukianov; Ekaterina S Komarova; Valeria I Marina; Yuliya V Zakalyukina; Mikhail V Biryukov; Tinashe P Maviza; Yan A Ivanenkov; Petr V Sergiev; Ilya A Osterman; Olga A Dontsova
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

2.  Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Authors:  Hans H Locher; Patrick Caspers; Thierry Bruyère; Susanne Schroeder; Philippe Pfaff; Andreja Knezevic; Wolfgang Keck; Daniel Ritz
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

3.  Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria.

Authors:  Elizabeth I Parkinson; Joseph S Bair; Bradley A Nakamura; Hyang Y Lee; Hani I Kuttab; Emma H Southgate; Stéphane Lezmi; Gee W Lau; Paul J Hergenrother
Journal:  Nat Commun       Date:  2015-04-24       Impact factor: 14.919

4.  Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase.

Authors:  Scott S Walker; Marc Labroli; Ronald E Painter; Judyann Wiltsie; Brad Sherborne; Nicholas Murgolo; Xinwei Sher; Paul Mann; Paul Zuck; Charles G Garlisi; Jing Su; Stacia Kargman; Li Xiao; Giovanna Scapin; Scott Salowe; Kristine Devito; Payal Sheth; Nichole Buist; Christopher M Tan; Todd A Black; Terry Roemer
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

5.  Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.

Authors:  Sebastian Franco-Ulloa; Giuseppina La Sala; Gian Pietro Miscione; Marco De Vivo
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

Review 6.  Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.

Authors:  Chetan Kumar Jain; Hemanta Kumar Majumder; Susanta Roychoudhury
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

7.  In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.

Authors:  Daisuke Oka; Naomitsu Yamaya; Takuya Kuno; Yuta Asakawa; Toshiyuki Shiragiku; Liang Chen; Jingbo Xue; Abudusaimi Mamuti; Fangguo Ye; Jiangqin Sun; Kinue Ohguro; Hisashi Miyamoto; Yukitaka Uematsu; Katsuya Inagaki; Jie-Fei Cheng; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

8.  DC-159a Shows Inhibitory Activity against DNA Gyrases of Mycobacterium leprae.

Authors:  Tomoyuki Yamaguchi; Kazumasa Yokoyama; Chie Nakajima; Yasuhiko Suzuki
Journal:  PLoS Negl Trop Dis       Date:  2016-09-28

9.  Acquisition of fluoroquinolone resistance leads to increased biofilm formation and pathogenicity in Campylobacter jejuni.

Authors:  Matthew V X Whelan; Laura Ardill; Kentaro Koide; Chie Nakajima; Yasuhiko Suzuki; Jeremy C Simpson; Tadhg Ó Cróinín
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.